Metformin

Metformin is a biguanide antihyperglycemic agent with a chemical lineage that traces to guanidine-containing compounds derived from the French lilac (Galega officinalis). It was synthesized in the 1920s, entered clinical use in Europe in the 1950s, and received FDA approval in the United States in 1994. It remains one of the most prescribed medications worldwide and is considered the standard first-line pharmacological treatment for type 2 diabetes mellitus in most major clinical guidelines.¹

Metformin's principal mechanism of action is inhibition of mitochondrial complex I in the electron transport chain, which activates AMP-activated protein kinase (AMPK) — a cellular energy sensor. This leads to reduced hepatic glucose production (the primary glycemic effect), decreased intestinal glucose absorption, and improved peripheral insulin sensitivity without stimulating insulin secretion.¹ Because it does not increase insulin release, metformin alone carries a very low intrinsic risk of hypoglycemia.

Metformin is available as immediate-release (IR) tablets taken two to three times daily with meals, and extended-release (ER) tablets that can be taken once daily with the evening meal.

Metformin is FDA-approved as adjunct therapy to diet and exercise to improve glycemic control in adults and in pediatric patients aged 10 and older with type 2 diabetes mellitus.¹

Off-label uses: Metformin is commonly prescribed off-label for polycystic ovary syndrome (PCOS) — to improve insulin resistance and menstrual regularity — and is the subject of active investigation as a longevity-oriented intervention in non-diabetic adults. The Targeting Aging with Metformin (TAME) trial, the first clinical trial designed to test whether a drug can delay multiple age-related diseases simultaneously, enrolled approximately 3,000 adults aged 65–79 without diabetes at multiple U.S. centers; results are expected approximately 2026–2027. The TAME trial's FDA-accepted design represents a landmark in geroscience, but whether metformin will demonstrate benefit in non-diabetic populations remains an open question — the evidence to date is largely observational and not yet established by randomized controlled trial data in healthy individuals.²

Immediate-release (IR): Starting dose 500 mg once or twice daily with meals; dose may be titrated by 500 mg per week as tolerated, up to a maximum of 2,550 mg per day in divided doses.¹

Extended-release (ER): Starting dose 500–1,000 mg once daily with the evening meal; may be titrated in 500 mg weekly increments to a maximum of 2,000–2,500 mg once daily depending on the product.

GI side effects are dose-related and are minimized by starting at the lowest effective dose, titrating slowly, and taking metformin with food. ER formulations generally produce fewer GI side effects than IR.

Real-world practice: Extended-release (ER) metformin taken once daily with the evening meal produces fewer gastrointestinal side effects than IR taken multiple times daily, and is commonly prescribed when GI tolerance is the limiting factor. If you experience GI issues on IR metformin, ask your prescribing physician about switching to the ER formulation before discontinuing.

Oral.

Store at controlled room temperature (68°F to 77°F / 20°C to 25°C). Extended-release tablets should be swallowed whole and not crushed, cut, or chewed. A tablet shell or ghost may be visible in the stool — this is normal for ER formulations and does not indicate incomplete absorption.¹

Boxed warning: Metformin-associated lactic acidosis — a rare but serious and potentially fatal buildup of lactic acid in the blood — can occur. Risk factors include renal impairment, age ≥65, hepatic impairment, hypoxic states, excessive alcohol intake, and use of contrast media for radiological procedures. Metformin is contraindicated in patients with eGFR below 30 mL/min/1.73 m². Metformin should be temporarily held before and after iodinated contrast procedures in patients with risk factors.¹

Additional considerations:¹

• Gastrointestinal effects: Diarrhea, nausea, vomiting, flatulence, and abdominal discomfort are the most common side effects, occurring in >5% of patients. These are typically dose-dependent and improve with time or dose reduction.
• Vitamin B12 deficiency: Metformin reduces intestinal absorption of vitamin B12, and long-term use is associated with decreased serum B12 levels in some patients. Annual hematological monitoring and B12 assessment every 2–3 years is recommended; supplementation may be needed.
• Exercise adaptation: Some research has suggested metformin may attenuate exercise-induced adaptations, including blunting improvements in aerobic capacity and potentially muscle hypertrophy responses. This area remains under investigation and the clinical significance is unclear for most patients, but individuals using metformin specifically for its longevity-associated properties while also engaged in structured training may wish to discuss timing and dose with their clinician.
• Alcohol: Excessive alcohol intake increases the risk of lactic acidosis; patients should be counseled accordingly.
• Renal monitoring: eGFR should be assessed before starting metformin, annually, and as clinically indicated.